NanoString Technologies Valuation
Is NSTG * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NSTG * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NSTG * (MX$29.32) is trading below our estimate of fair value (MX$268.83)
Significantly Below Fair Value: NSTG * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NSTG *?
Other financial metrics that can be useful for relative valuation.
What is NSTG *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$38.41m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.2x |
Enterprise Value/EBITDA | -1.3x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does NSTG *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 7.6x | ||
IPA ImmunoPrecise Antibodies | 1.9x | 19.4% | US$33.7m |
RPID Rapid Micro Biosystems | 1.5x | 27.3% | US$34.4m |
4583 Chiome Bioscience | 10x | n/a | JP¥7.0b |
2397 DNA Chip Research | 16.8x | n/a | JP¥7.5b |
NSTG * NanoString Technologies | 0.2x | 16.2% | Mex$38.4m |
Price-To-Sales vs Peers: NSTG * is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (1.9x).
Price to Earnings Ratio vs Industry
How does NSTG *'s PE Ratio compare vs other companies in the Global Life Sciences Industry?
Price-To-Sales vs Industry: NSTG * is good value based on its Price-To-Sales Ratio (0.2x) compared to the Global Life Sciences industry average (4.2x).
Price to Sales Ratio vs Fair Ratio
What is NSTG *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.2x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate NSTG *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.